Radiation drug for people with head and neck cancer on immunotherapy
Part of Cancer clinical trials.
This study tests a radioactive drug called Y-NM600 that may help treat head and neck cancer that has spread. It is given to people who are already receiving an immunotherapy drug (like Keytruda or Opdivo) and whose cancer is stable or slightly growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer (squamous cell carcinoma) that has spread to other parts of the body.
- You are currently taking one of these immunotherapy drugs: Keytruda, Opdivo, Tecentriq, Bavencio, Imfinzi, Libtayo, or Jemperli (alone or with other immunotherapy).
- Your cancer is stable or shows signs of growing but your doctor wants to continue your immunotherapy.
- You have at least one tumor that can be seen on a scan.
- You are generally able to take care of yourself (ECOG score 0-2) and expected to live at least 6 months.
- You have adequate kidney, liver, and blood cell counts (your doctor will check).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding an investigational drug called JNJ-90301900 to standard chemotherapy and radiation therapy works better for people with certain advanced head and neck cancers (like mouth, throat, and voice box) that have not spread to other parts of the body.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This study tests whether adding two different drugs (nimotuzumab and benmelstobart) to standard radiation therapy after surgery can help improve outcomes for people with intermediate-risk head and neck cancer. It looks at whether the combination slows cancer growth or reduces the chances of it coming back.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial compares radiation therapy alone versus radiation therapy plus a targeted drug called nimotuzumab for people with advanced head and neck cancer who cannot take cisplatin chemotherapy. The goal is to see if adding nimotuzumab improves outcomes.
This trial tests a personalized radiotherapy approach after a few rounds of chemo-immunotherapy for people with HPV-negative head and neck cancer. It aims to adjust the radiation dose based on how the tumor responds, possibly reducing side effects while still controlling the cancer.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.